| Literature DB >> 24936238 |
Qi Shi1, Shaoman Yin2, Stefan Kaluz3, Nanting Ni4, Narra Sarojini Devi2, Jiyoung Mun5, Danzhu Wang4, Krishna Damera4, Weixuan Chen4, Sarah Burroughs4, Suazette Reid Mooring4, Mark M Goodman6, Erwin G Van Meir7, Binghe Wang4, James P Snyder8.
Abstract
Hypoxia inducible factors (HIFs) are transcription factors that activate expression of multiple gene products and promote tumor adaptation to a hypoxic environment. To become transcriptionally active, HIFs associate with cofactors p300 or CBP. Previously, we found that arylsulfonamides can antagonize HIF transcription in a bioassay, block the p300/HIF-1α interaction, and exert potent anticancer activity in several animal models. In the present work, KCN1-bead affinity pull down, (14)C-labeled KCN1 binding, and KCN1-surface plasmon resonance measurements provide initial support for a mechanism in which KCN1 can bind to the CH1 domain of p300 and likely prevent the p300/HIF-1α assembly. Using a previously reported NMR structure of the p300/HIF-1α complex, we have identified potential binding sites in the p300-CH1 domain. A two-site binding model coupled with IC50 values has allowed establishment of a modest ROC-based enrichment and creation of a guide for future analogue synthesis.Entities:
Keywords: HIF arylsulfonamide inhibitors; KCN1; QSAR; binding model; hypoxia; p300; solid tumors
Year: 2012 PMID: 24936238 PMCID: PMC4056939 DOI: 10.1021/ml300042k
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345